Research Topics
| Ronald N MarcusSummaryAffiliation: Bristol-Myers Squibb Country: USA Publications
| Collaborators
|
Detail Information
Publications
Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter studyRonald N Marcus
Department of Research and Development, Bristol Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA
J Clin Psychiatry 72:1270-6. 2011..Evaluate the long-term safety and tolerability of aripiprazole in the treatment of irritability in pediatric subjects (6-17 years) with autistic disorder...- Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized studyRonald Marcus
Bristol Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA
Bipolar Disord 13:133-44. 2011.... 
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)Linda Hanssens
Bristol Myers Squibb Company, Parc de l Alliance, Avenue de Finlande, 8, B 1420 Braine l Alleud, Belgium
BMC Psychiatry 8:95. 2008....- Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label studyRonald N Marcus
Bristol Myers Squibb, Wallingford, Connecticut, USA
J Child Adolesc Psychopharmacol 21:229-36. 2011..To report the long-term efficacy of aripiprazole in the treatment of irritability in children and adolescents (ages 6-17 years) with autistic disorder... - Aripiprazole in the treatment of irritability in children and adolescents with autistic disorderRandall Owen
Bristol Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, USA
Pediatrics 124:1533-40. 2009.... 
Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressantsRobert M Berman
Neuroscience Global Clinical Research at Bristol Myers Squibb, Wallingford, CT 06492, USA
CNS Spectr 14:197-206. 2009..This trial evaluated the efficacy and safety of adjunctive aripiprazole versus antidepressant monotherapy in patients with MDD and independently replicated the positive findings of two similar trials...- A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorderRonald N Marcus
Bristol Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA
J Am Acad Child Adolesc Psychiatry 48:1110-9. 2009..To evaluate the short-term efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents with autistic disorder... - The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled studyRonald N Marcus
Bristol Myers Squibb, Wallingford, CT 06492, USA
J Clin Psychopharmacol 28:156-65. 2008..1%] vs adjunctive aripiprazole [3.7%]). Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT... - Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapyJames Craig Nelson
Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA
Int Clin Psychopharmacol 27:125-33. 2012..12%, respectively, P<0.0001). The numbers needed to treat with aripiprazole+ADT were six for response and eight for remission. Aripiprazole augmentation had a rapid and clinically meaningful effect in ADT minimal responders... - The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled studyRobert M Berman
Bristol Myers Squibb Co, Wallingford, Conn 06492, USA
J Clin Psychiatry 68:843-53. 2007.... - Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorderRobert M Berman
Neuroscience Global Clinical Research Bristol Myers Squibb, Wallingford, CT, USA
Neuropsychiatr Dis Treat 7:303-12. 2011..Effective management of major depressive disorder often includes the long-term use of multiple medications, and the longer-term utility and safety of adjunctive aripiprazole has not been evaluated in a controlled setting... - Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placeboGilbert J L'italien
Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
J Clin Psychiatry 68:1510-6. 2007....